The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
With Upsher-Smith Deal Inked, Sawai Looks to Make US Market Its Second Biz Pillar
Sawai Pharmaceutical is looking to grow its US business into its second largest pillar after Japan, now that it has clinched a US$1 billion deal to acquire local peer Upsher-Smith Laboratories, which marks the biggest acquisition ever for a Japanese…
To read the full story
Related Article
- Sawai Group President Says US Biz Exit was Due to Lack of Foresight
February 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
- Sawai’s Upsher-Smith Acquisition Completed
June 2, 2017
- Sawai to Buy US Generic Maker Upsher-Smith
April 20, 2017
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…